Business
Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx
Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that it has entered into a Commercial Manufacturing Agreement with SpectronRx for Clarity's lead diagnostic product, 64Cu-SAR-bisPSMA.
About this update from Clarity Pharmaceuticals Ltd.
[{"type":"text","content":"Highlights","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Clarity has entered into a Commercial Manufacturing Agreement with SpectronRx for 64Cu-SAR-bisPSMA.","length":99,"tagName":"p"}]},{"val":[{"type":"text","content":"SpectronRx's facility in Indiana will provide on-demand commercial-scale manufacturing of both copper-64 and 64Cu-SAR-bisPSMA under one roof and enables distribution to all 50 states.","length":187,"tagName":"p"}]},{"val":[{"type":"text","content":"SpectronRx will expand current production to up to 400,000 patient-ready doses of 64Cu-SAR-bisPSMA annually at the Indiana facility by the time of commercialisation.","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"The Agreement also includes an option to expand into similar additional sites, substantially increasing the manufacturing capacity of patient-ready doses of 64Cu-SAR-bisPSMA in regional hubs spread throughout the US.","length":216,"tagName":"p"}]},{"val":[{"type":"text","content":"The Commercial Supply Agreement supplements Clarity's current supply and manufacturing agreements for isotope and product, creating a multi-layered and abundant approach. This allows for nationally and regionally centralised as well as local production of isotope and final product enabled by the characteristics and optimal half-life of copper-64.","length":352,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1019,"olType":false},{"type":"text","content":"SYDNEY, June 17, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that it has entered into a Commercial Manufacturing Agreement with SpectronRx for Clarity's lead diagnostic product, 64Cu-SAR-bisPSMA.","length":434,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Clarity Pharmaceuticals)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Clarity Pharmaceuticals)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":98,"url":"https://media.zenfs.com/en/prnewswire.com/2ced23e8ddb3b1ec6ef537b99f6e12a7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fkXRk3krOQ3AG6qYDObpxg--/YXBwaWQ9aGln...